Abstract
This study aims to investigate the therapeutic potential of autohemotherapy in stimulating macrophages to remove β-amyloid plaques in patients with Alzheimer's disease (AD), using the DAMEV (Alzheimer's Disease, Brain, and Vegetative Death) method as an integrative diagnostic model. DAMEV allows for the correlation of brain metabolic patterns detected by FDG-PET-CT and PET-Amyloid with varying degrees of brain involvement, providing targets for monitoring disease progression and therapeutic response. The central hypothesis is that autohemotherapy, by activating the mononuclear phagocytic system, stimulates macrophages capable of modulating brain inflammation and removing amyloid plaques, promoting metabolic and cognitive improvement. The study proposes a planned, double- blind, and controlled clinical trial with longitudinal assessment by functional molecular imaging and neuropsychological assessment. The proposed translational approach is expected to contribute to the advancement of complementary therapies and to the understanding of the boundaries between neuronal degeneration, consciousness and metabolic reversibility in the DAMEV spectrum.